Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson’s disease: insights from the PPMI cohort

Puntos clave

• Cerebrospinal fluid dopamine 3-O-sulfate is significantly associated with motor complications in Parkinson’s disease.
• A key finding shows that higher levels of this biomarker correlate with increased risk of motor issues over time.
• Analysis focused on data from the PPMI cohort, emphasizing a novel approach to identifying complications in Parkinson’s.
• These findings highlight the importance of cerebrospinal fluid biomarkers in monitoring disease progression and treatment outcomes.